News
Affimed Announces Positive Results Demonstrating Safety and Efficacy of Acimtamig and AlloNK ® Combination in Relapsed/Refractory Classical Hodgkin Lymphoma (R/R cHL) Patients
By: investing_au
- Dec 09 2024
- 0
- 0 Views
ONLY AVAILABLE IN PAID PLANS